antiretroviral therapy

Long-Acting Injectable ART Superior to Oral Regimens in Patients with HIV Adherence Challenges: Insights from the LATITUDE Trial

By MedXY 02/22/2026

The LATITUDE trial reveals that monthly injectable cabotegravir-rilpivirine significantly reduces treatment failure compared to standard oral ART in individuals with HIV who struggle with daily medication adherence, potentially reshaping clinical guidelines for vulnerable patient populations.

Infectious Diseases news

Doravirine and Islatravir Combination Proves Non-Inferior to B/F/TAF: A New Era for Two-Drug HIV Maintenance

By MedXY 02/15/2026

Phase 3 trial results demonstrate that a daily fixed-dose combination of doravirine and islatravir effectively maintains virological suppression in adults with HIV-1, offering a comparable and safe alternative to standard integrase inhibitor-based regimens.

Infectious Diseases news

Twice-Daily Bictegravir-Based Therapy Proves Effective and Safe During Rifampicin-Based Tuberculosis Treatment: Insights from the INSIGHT Trial

By MedXY 01/14/2026

The Phase 2b INSIGHT study demonstrates that twice-daily bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) is highly effective and safe for treating HIV in patients receiving rifampicin-based tuberculosis therapy, achieving over 94 percent viral suppression at 24 weeks.

HIV/AIDS Infectious Diseases news

Next-Day HIV Viral Load Results Improve Time to Care for People Living with HIV but Show Limited Impact on Prevention Linkage

By MedXY 12/21/2025

This randomized clinical trial explored if next-day HIV viral load results improve linkage to care. While overall linkage rates remained unchanged, the intervention significantly accelerated care initiation for individuals already living with HIV, suggesting a nuanced benefit for treatment over prevention pathways.

HIV/AIDS Infectious Diseases news

Accelerated Epigenetic Aging in HIV: Insights from a Systematic Review

By MedXY 10/22/2025

Systematic review evidence supports accelerated epigenetic aging in people living with HIV compared to uninfected individuals, highlighting the need for further research considering antiretroviral therapy and confounding factors.

HIV/AIDS Infectious Diseases Specialties

Long-Term Health Risks in HIV Patients with Immune Non-Response Despite Antiretroviral Therapy

By MedXY 10/22/2025

Immune non-response despite ART in people with HIV significantly increases risk of both AIDS-defining and non-AIDS-defining comorbidities, underscoring the need for enhanced risk assessment beyond CD4+ T-cell counts.

Dermatology HIV/AIDS Specialties

Evolving Dermatologic Landscape in HIV: Prevalence, Incidence, and Risk Factors in the Modern ART Era from the DC Cohort

By MedXY 10/22/2025

Despite advances in antiretroviral therapy, dermatologic diseases remain prevalent in people with HIV, with incidence declining yet significant disparities persisting related to immune status, demographics, and structural factors.

HIV/AIDS Infectious Diseases Public Health Specialties

HIV Among Older Adults in Sub-Saharan Africa: Epidemiology, Risks, and Treatment Insights from the AWI-Gen Longitudinal Study

By MedXY 10/20/2025

This multicentre longitudinal cohort study reveals significant HIV prevalence and incidence among adults aged 40 and older in sub-Saharan Africa, highlighting age, gender, education, and rural residency as critical factors influencing HIV risk and treatment outcomes.

Cardiology HIV/AIDS news Specialties

Early HIV Treatment and Cardiovascular Health: Insights from the START Study

By MedXY 10/09/2025

Early ART initiation in HIV-positive adults with high CD4+ counts shows no overall cardiovascular benefit, but reduced CVD events in women suggest potential sex-specific effects needing further study.

HIV/AIDS news Specialties

Efficacy of Bictegravir-Based Regimen vs. Ritonavir-Boosted Protease Inhibitors in HIV Patients on Second-Line Therapy in Haiti: Insights from a Randomized Non-Inferiority Trial

By MedXY 09/21/2025

A randomized trial in Haiti demonstrates that switching to bictegravir, emtricitabine, and tenofovir alafenamide is non-inferior to ritonavir-boosted protease inhibitors in maintaining viral suppression among second-line HIV therapy patients.

Clinical Updates HIV/AIDS news Specialties

Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial

By MedXY 08/03/2025

The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.

Clinical Updates HIV/AIDS news Specialties

Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial

By MedXY 08/02/2025

TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.